Deaminet 2026: Breakthroughs in Base Editing, Deaminase Biology, and Therapeutic Translation

Key Takeaways

• Base/prime editors distribution surged, 2024 tools top-requested 2025
• PE6d gains efficiency but risks overextension insertions
• beCasKAS reveals 460× more off‑targets than standard assays
• PERT converts tRNA to suppressor, rescuing nonsense mutations
• RNA editing platforms enter clinical trials, expanding therapeutic options

Pulse Analysis

Addgene’s longitudinal data reveal a paradigm shift in gene‑editing adoption: tools deposited as early as 2013 still account for a measurable share of distributions, while 2024‑deposited base and prime editors quickly rose to the top of the 2025 request list. This sustained demand reflects both the durability of foundational CRISPR platforms and the community’s ability to integrate structural breakthroughs—such as cryo‑EM‑guided engineering of PE6d and ABE8e—into next‑generation editors. The rapid diffusion of these tools shortens the interval between discovery and widespread experimental use, amplifying collaborative innovation across academia and industry.

Safety has become a focal point as editing moves toward clinical applications. Emerging assays like beCasKAS, which couples Cas9 binding detection with deamination outcomes, and Inrich‑seq, which captures the inosine intermediate, expose thousands of off‑target sites missed by conventional methods. By providing modality‑matched, high‑resolution maps of unintended edits, these technologies enable developers to meet stringent regulatory expectations and mitigate immunogenic risks. The heightened sensitivity also informs rational enzyme redesign, driving a feedback loop between safety profiling and editor optimization.

Therapeutic translation is now tangible. Prime‑editing strategies such as PERT repurpose endogenous tRNAs to suppress premature stop codons, achieving notable protein rescue in disease models, while oDNA donors circumvent innate immune activation, allowing higher‑dose, non‑viral DNA delivery. Prime Medicine’s PM577a demonstrates >80% correction of the ATP7B mutation in Wilson’s disease without detectable off‑targets, positioning prime editing for IND filing in early 2026. Concurrently, RNA‑editing platforms—AIMers targeting hepatic A→I conversion, adaptamers enabling drug‑responsive gene regulation, and editopes generating neoantigens—are advancing through early‑phase trials. Together, these advances illustrate a maturing ecosystem where DNA and RNA editing complement each other, expanding the therapeutic horizon for genetic and oncologic diseases.